Study 7 of 22Cagrilintide (AM833) literaturebiorxiv-preprint · Meta-analysis2025
Cagrilintide–Semaglutide Combination Therapy Versus Monotherapy or Placebo: A Systematic Review and Meta-Analysis
The abstract is not available, preventing any conclusions about the study's findings or implications.
Where it sits
this study against the rest of the cagrilintide (am833) corpus3
Preclinical
4
Observational
0
Open-label
4
Randomised
11
Reviews · this one
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.20). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2025
Background
The study appears to address the efficacy of combination therapy with Cagrilintide and Semaglutide compared to monotherapy or placebo. This is relevant as both peptides have been investigated for weight management and metabolic disorders, but their combined effect is less understood.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Without access to the abstract or full text, it is impossible to determine how the findings compare to existing literature or their clinical significance. The lack of detailed information limits any interpretation.
Key findings
- Not reported in abstract.
Limitations
- Abstract not available
- Preprint status
- Unknown sample size
- Unknown study design
- Unknown outcome measures
Elsewhere in the Cagrilintide (AM833) corpus
AEfficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis.Diabetes, obesity & metabolism · 2023 · n=4554 · -1.87 percentage points HbA1c reduction vs placebo (95% CrI, -2.08 to -1.62)reviewCContinued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats.Molecular metabolism · 2026 · CS reduced energy intake (EI) and preserved total energy expenditure (EE), explaining 86% and 14% of weight loss efficacy respectively.AnimalADesign and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3).American heart journal · 2026 · n=7076 · 7076 adults randomized between 1/2023-12/2024.HumanAWeight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.Obesity (Silver Spring, Md.) · 2026 · n=40731 · Coagonists RR=0.43, 95% CI: 0.19 to 0.97reviewABenefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.Annals of internal medicine · 2026 · n=112511 · 112,511 participants across 69 studies.reviewAMaximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.Naunyn-Schmiedeberg's archives of pharmacology · 2026 · n=8069 · MD = -13.99 kg vs placebo; 95% CI = -18.38 to -9.61; p < 0.00001review